Back to top

dna-sequencing: Archive

Zacks Equity Research

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.

ALNYPositive Net Change PFEPositive Net Change GILDNo Net Change QURENegative Net Change